AI-generated summary
The authors retrospectively reviewed 117 head and neck cancer patients who received chemoradiotherapy with concurrent photobiomodulation. They report lower rates of some toxicities, including grade 2-3 odynophagia and persistent dysphagia, among patients receiving 10 or more sessions. The retrospective design and lack of a control group limit causal conclusions.
- Participants
- 117
- Who or what was studied
- Adult patients with head and neck cancer undergoing definitive or adjuvant chemoradiotherapy with concomitant photobiomodulation, treated between May 2021 and July 2024
- Wavelengths
- 620, 820, 650 nm
- Limits stated in the abstract
- The study is retrospective, lacks a control group, and the authors state that these limits prevent causal inference.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on mdpi.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 820 nm, 650 nm
- Energy density (fluence)
- 12 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, GRADE, Oral mucositis, Control group, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.